Patents by Inventor Carl-Magnus Anderson

Carl-Magnus Anderson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES
    Publication number: 20120277221
    Abstract: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
    Type: Application
    Filed: June 29, 2012
    Publication date: November 1, 2012
    Inventors: David M. WEINER, Robert E. Davis, Mark R. Brann, Carl-Magnus A. Anderson, Allan K. Uldam
  • Muscarinic agonists
    Patent number: 7238713
    Abstract: Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: July 3, 2007
    Assignee: Acadia Pharmaceuticals, Inc.
    Inventors: Carl-Magnus A. Anderson, Bo Lennart M. Friberg, Niels Skjaerbaek, Tracy A. Spalding, Allan K. Uldam
  • Muscarinic agonists
    Publication number: 20050113357
    Abstract: Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.
    Type: Application
    Filed: July 17, 2003
    Publication date: May 26, 2005
    Inventors: Carl-Magnus Anderson, Bo Friberg, Niels Skjaerbaek, Tracy Spalding, Allan Uldam